Vanda Pharmaceuticals (VNDA) Current Ratio: History & Chart

Vanda Pharmaceuticals Inc.(VNDA)

Biotechnology · Washington, DC

$4.52-0.06 (-1.31%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.

Washington, DC

533 employees

www.vandapharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Mihael H. Polymeropoulos

View full financials

VNDA Current Ratio Metrics

CURRENT RATIO

1.61

CURRENT RATIO AVG TTM

2.51

CURRENT RATIO AVG 3Y

4.04

CURRENT RATIO AVG 5Y

4.73

CURRENT RATIO AVG 10Y

4.70

CURRENT RATIO AVG 15Y

4.43

CURRENT RATIO AVG 20Y

4.65

CURRENT VS TTM AVG

-35.68%

CURRENT VS 3Y AVG

-60.04%

CURRENT VS 5Y AVG

-65.93%

CURRENT VS 10Y AVG

-65.67%

CURRENT VS 15Y AVG

-63.62%

CURRENT VS 20Y AVG

-65.36%

SECTOR MEDIAN · HEALTHCARE

3.76

median of 873 covered companies

CURRENT VS SECTOR MEDIAN

-57.12%

vs the sector median at left

NAME	MARKET CAP	CURRENT RATIO	TTM	3Y	5Y
Vanda Pharmaceuticals Inc. (VNDA)	$271.81M	1.61	2.51	4.04	4.73
Rocket Pharmaceuticals, Inc. (RCKT)vs ›	$270.80M	9.24	7.84	8.19	10.90
Fate Therapeutics, Inc. (FATE)vs ›	$266.92M	4.85	6.69	6.56	6.64
SAB Biotherapeutics, Inc. (SABS)vs ›	$266.59M	9.22	6.22	4.84	4.06
EyePoint Pharmaceuticals, Inc. (EYPT)vs ›	$265.78M	4.50	8.35	6.79	6.91
Scribe Therapeutics Inc. (SCTX)vs ›	$264.25M	N/A	N/A	N/A	N/A
BridgeBio Oncology Therapeutics Inc. (BBOT)vs ›	$280.37M	4.69	11.27	11.27	11.27
TriSalus Life Sciences, Inc. (TLSI)vs ›	$262.92M	5.35	2.41	1.69	2.06
Fulcrum Therapeutics, Inc. (FULC)vs ›	$281.54M	31.35	25.02	20.04	16.03
Inhibikase Therapeutics, Inc. (IKT)vs ›	$261.43M	15.82	24.04	14.70	12.06

NAME

MARKET CAP

CURRENT RATIO

TTM

Vanda Pharmaceuticals Inc. (VNDA)

$271.81M

1.61

2.51

4.04

4.73

Rocket Pharmaceuticals, Inc. (RCKT)vs ›

$270.80M

9.24

7.84

8.19

10.90

Fate Therapeutics, Inc. (FATE)vs ›

$266.92M

4.85

6.69

6.56

6.64

SAB Biotherapeutics, Inc. (SABS)vs ›

$266.59M

9.22

6.22

4.84

4.06

EyePoint Pharmaceuticals, Inc. (EYPT)vs ›

$265.78M

4.50

8.35

6.79

6.91

Scribe Therapeutics Inc. (SCTX)vs ›

$264.25M

N/A

BridgeBio Oncology Therapeutics Inc. (BBOT)vs ›

$280.37M

4.69

11.27

TriSalus Life Sciences, Inc. (TLSI)vs ›

$262.92M

5.35

2.41

1.69

2.06

Fulcrum Therapeutics, Inc. (FULC)vs ›

$281.54M

31.35

25.02

20.04

16.03

Inhibikase Therapeutics, Inc. (IKT)vs ›

$261.43M

15.82

24.04

14.70

12.06

Current Ratio FAQ

What is the current ratio for Vanda Pharmaceuticals Inc. (VNDA)?

The current ratio for VNDA stock is 1.61.

Is Vanda Pharmaceuticals Inc.'s current ratio high or low?

The current ratio of 1.61 is 66% below its 5-year average of 4.73, near the low end of its 5-year range (1.61–6.43).

What is the TTM average current ratio for Vanda Pharmaceuticals Inc. (VNDA)?

The TTM average current ratio for VNDA stock is 2.51.

What is the 3Y average current ratio for Vanda Pharmaceuticals Inc. (VNDA)?

The 3Y average current ratio for VNDA stock is 4.04.

What is the 5Y average current ratio for Vanda Pharmaceuticals Inc. (VNDA)?

The 5Y average current ratio for VNDA stock is 4.73.

What is the 10Y average current ratio for Vanda Pharmaceuticals Inc. (VNDA)?

The 10Y average current ratio for VNDA stock is 4.70.

What is the 15Y average current ratio for Vanda Pharmaceuticals Inc. (VNDA)?

The 15Y average current ratio for VNDA stock is 4.43.

What is the 20Y average current ratio for Vanda Pharmaceuticals Inc. (VNDA)?

The 20Y average current ratio for VNDA stock is 4.65.

DATE	CURRENT RATIO
2026-06-30	1.61
2026-03-31	2.16
2025-12-31	2.39
2025-09-30	3.12
2025-06-30	3.25
2025-03-31	3.93
2024-12-31	4.39
2024-09-30	4.85
2024-06-30	4.68
2024-03-31	4.71
2023-12-31	4.94
2023-09-30	6.32
2023-06-30	6.10
2023-03-31	5.69
2022-12-31	5.68
2022-09-30	5.47
2022-06-30	5.62
2022-03-31	5.42
2021-12-31	6.43
2021-09-30	6.41
2021-06-30	6.20
2021-03-31	6.82
2020-12-31	6.21
2020-09-30	6.35
2020-06-30	6.18
2020-03-31	6.09
2019-12-31	5.95
2019-09-30	4.67
2019-06-30	5.05
2019-03-31	5.17
2018-12-31	5.64
2018-09-30	6.03
2018-06-30	5.74
2018-03-31	3.93
2017-12-31	2.41
2017-09-30	2.37
2017-06-30	2.31
2017-03-31	2.31
2016-12-31	3.46
2016-09-30	3.36
2016-06-30	3.10
2016-03-31	2.95
2015-12-31	3.25
2015-09-30	3.79
2015-06-30	3.86
2015-03-31	5.10
2014-12-31	18.20
2014-09-30	1.67
2014-06-30	1.86
2014-03-31	2.32
2013-12-31	4.13
2013-09-30	4.61
2013-06-30	3.39
2013-03-31	3.63
2012-12-31	3.90
2012-09-30	4.04
2012-06-30	4.36
2012-03-31	4.94
2011-12-31	4.85
2011-09-30	4.90
2011-06-30	5.83
2011-03-31	6.16
2010-12-31	6.46
2010-09-30	6.42
2010-06-30	6.03
2010-03-31	6.15
2009-12-31	6.75
2009-09-30	2.99
2009-06-30	2.77
2009-03-31	12.57
2008-12-31	14.00
2008-09-30	13.72
2008-06-30	6.72
2008-03-31	7.00
2007-12-31	6.81
2007-09-30	7.11
2007-06-30	13.61
2007-03-31	18.62
2006-12-31	3.71
2006-09-30	4.44
2006-06-30	3.66
2006-03-31	2.05
2005-12-31	6.59
2005-09-30	0.00
2005-06-30	0.00
2005-03-31	0.00

DATE

CURRENT RATIO

2026-06-30

1.61

2026-03-31

2.16

2025-12-31

2.39

2025-09-30

3.12

2025-06-30

3.25

2025-03-31

3.93

2024-12-31

4.39

2024-09-30

4.85

2024-06-30

4.68

2024-03-31

4.71

2023-12-31

4.94

2023-09-30

6.32

2023-06-30

6.10

2023-03-31

5.69

2022-12-31

5.68

2022-09-30

5.47

2022-06-30

5.62

2022-03-31

5.42

2021-12-31

6.43

2021-09-30

6.41

2021-06-30

6.20

2021-03-31

6.82

2020-12-31

6.21

2020-09-30

6.35

2020-06-30

6.18

2020-03-31

6.09

2019-12-31

5.95

2019-09-30

4.67

2019-06-30

5.05

2019-03-31

5.17

2018-12-31

5.64

2018-09-30

6.03

2018-06-30

5.74

2018-03-31

3.93

2017-12-31

2.41

2017-09-30

2.37

2017-06-30

2.31

2017-03-31

2.31

2016-12-31

3.46

2016-09-30

3.36

2016-06-30

3.10

2016-03-31

2.95

2015-12-31

3.25

2015-09-30

3.79

2015-06-30

3.86

2015-03-31

5.10

2014-12-31

18.20

2014-09-30

1.67

2014-06-30

1.86

2014-03-31

2.32

2013-12-31

4.13

2013-09-30

4.61

2013-06-30

3.39

2013-03-31

3.63

2012-12-31

3.90

2012-09-30

4.04

2012-06-30

4.36

2012-03-31

4.94

2011-12-31

4.85

2011-09-30

4.90

2011-06-30

5.83

2011-03-31

6.16

2010-12-31

6.46

2010-09-30

6.42

2010-06-30

6.03

2010-03-31

6.15

2009-12-31

6.75

2009-09-30

2.99

2009-06-30

2.77

2009-03-31

12.57

2008-12-31

14.00

2008-09-30

13.72

2008-06-30

6.72

2008-03-31

7.00

2007-12-31

6.81

2007-09-30

7.11

2007-06-30

13.61

2007-03-31

18.62

2006-12-31

3.71

2006-09-30

4.44

2006-06-30

3.66

2006-03-31

2.05

2005-12-31

6.59

2005-09-30

0.00

2005-06-30

0.00

2005-03-31

0.00

Current Ratio: 1.61

VNDA Current Ratio

VNDA Average Current Ratio Chart

VNDA Current vs Average Current Ratio Chart

VNDA Current Ratio Metrics

VNDA Competitors' Current Ratio

Liquidity Analysis

Current Ratio Formula & Definition

Current Ratio FAQ

VNDA Current Ratio History

Related Metrics